Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections

US11230543B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Haifeng Tang · South San Francisco, US
• Weiguo Liu · San Leandro, US
• Fa-Xiang Ding · Staten Island, US
• Wanying Sun · Edison, US
• Yi Zang · Princeton Junction, US
• Weidong Pan · Somerville, US
• Anthony Ogawa · New Providence, US
• Linda Brockunier · Orange, US
• Xianhai Huang · Hackettstown, US
• Hongwu Wang · Westfield, US
• Rudrajit Mal · Edison, US
• Tesfaye Biftu · Belmont, US
• Min K. Park · Whippany, US
• Yan Guo · Westfield, US
• Jinlong Jiang · Scotch Plains, US
• Helen Chen · Livingston, US
• Christopher W. Plummer · Hoboken, US

Key dates

• Filing date: Jun 25, 2020
• Grant date: Jan 25, 2022
• Expiry date: Jun 25, 2040

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, A2, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.